TheStockAdvisors note that the recent pull back in shares of Celgene make for a good buying opportunity. They say that despite lowering revenue guidance, Celgene is still a "great growth story."
To contrast, Zacks recently lowered the rating on the stock to a Hold with a $45 price target. 52 week low is $36. If you believe in the growth story, now would be a good time to get in.